Hennion & Walsh Asset Management Inc. Raises Stock Position in Celcuity Inc. (NASDAQ:CELC)

Hennion & Walsh Asset Management Inc. raised its holdings in shares of Celcuity Inc. (NASDAQ:CELC) by 34.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 73,026 shares of the company’s stock after acquiring an additional 18,809 shares during the quarter. Hennion & Walsh Asset Management Inc. owned approximately 0.21% of Celcuity worth $1,089,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CELC. nVerses Capital LLC bought a new stake in Celcuity during the 3rd quarter valued at approximately $33,000. Quest Partners LLC raised its position in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Celcuity in the third quarter worth $119,000. BNP Paribas Financial Markets lifted its holdings in shares of Celcuity by 78.5% in the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after buying an additional 3,930 shares in the last quarter. Finally, Commonwealth Equity Services LLC boosted its position in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after acquiring an additional 1,500 shares during the last quarter. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on CELC. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a report on Thursday, August 15th. Stifel Nicolaus boosted their target price on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Monday, October 7th. Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Leerink Partners started coverage on Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Celcuity in a report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $29.17.

Celcuity Trading Down 1.2 %

Shares of CELC stock opened at $15.61 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. The stock’s 50 day simple moving average is $15.51 and its two-hundred day simple moving average is $16.25. The company has a market cap of $547.93 million, a PE ratio of -5.62 and a beta of 0.75. Celcuity Inc. has a 1 year low of $9.36 and a 1 year high of $22.19.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period in the prior year, the company earned ($0.66) earnings per share. Research analysts predict that Celcuity Inc. will post -2.54 earnings per share for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.